

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO
**INFORMATION DISCLOSURE
 STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number 10/605,824
 Filing Date 10/29/2003
 First Named Inventor James C. Kennedy
 Group Art Unit 1617
 Examiner Name Unassigned
 Attorney Docket Number 067286-0276

Sheet

1

of

6

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	A1	5,211,938		KENNEDY et al.	05/93	
	A2	5,219,878		RINGUET et al.	06/93	
	A3	5,163,990		REBEIZ	11/92	
	A4	5,200,427		REBEIZ et al.	04/93	
	A5	5,079,262		KENNEDY et al.	01/92	
	A6	5,234,940		KENNEDY et al.	08/93	
	A7	4,772,681		FUKUDA et al.	09/88	
	A8	4,977,177		BOMMER et al.	12/90	
	A9	5,004,811		BOMMER et al.	04/91	
	A10	5,127,938		REBEIZ	07/92	
	A11	5,422,093		KENNEDY et al.	06/95	
	A12	4,932,934		DOUGHERTY et al.	06/90	
	A13	5,425,728		TANKOVICH	06/95	
	A14	5,226,907		TANKOVICH	07/93	
	A15	5,423,803		TANKOVICH et al.	06/95	
	A16	5,484,803		RICHTER	01/96	
	A17	5,955,490		KENNEDY, et al.	09/99	
	A18	5,705,518		RICHTER et al.	06/98	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	A19	EP	0 233 701			08/87		
	A20	WO	95/07077			03/95		

Examiner Signature

Date Considered

9/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO			Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Application Number	10/605,824
			Filing Date	10/29/2003
(use as many sheets as necessary)			First Named Inventor	James C. Kennedy
			Group Art Unit	1617
Sheet 2 of 6			Examiner Name	Unassigned
			Attorney Docket Number	067286-0276

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
J	A21	WO	93/08715			05/93		
	A22	WO	91/01727			02/91		
	A23	WO	95/31189			11/23/95		
	A24	WO	94/06424			3/31/94		
	A25	WO	95/05813			3/2/95		
	A26	WO	93/20810			10/28/93		
	A27	WO	94/12239			6/9/94		

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
✓	A28	BOEHNCKE, et al., Treatment of Psoriasis by Topical Photodynamic Therapy with Polychromatic Light, <i>The Lancet</i> , 343:801, March 1994			
	A29	FUKUDA et al., Photodynamic Action of Endogenously synthesized Porphyrins from Aminolevulinic, <i>Int. J. Biochem.</i> , 25:10; 1395-98, 1993			
	A30	LOH et al., Endogenous Porphyrin Distribution-Induced by 5-Aminolaevulinic Acid. . . , <i>J. Photochem. Photobiol.</i> , 20:47-54, 1993			
	A31	VAN DER VEEN et al., In Vivo Fluorescence Kinetics and Photodynamic Therapy Using 5-Aminolaevulinic, <i>Br. J. Cancer</i> , 70:867-72, 1994			
	A32	GRANT et al., Photodynamic Therapy of Normal Rat Arteries After Photosensitisation Using . . . , <i>Br. J. Cancer</i> , 70:72-78, 1994			
	A33	German Abstract No. A78035910, "Investigation and Therapy In Dermatology With Dye Lasers", ANDERS et al., pp. 772, (1977)			
	A34	QIAN et al., "A Comparison Of Different Photosensitizing Dyes With Respect To Uptake C3H-Tumors and Tissues Of Mice", <i>Cancer Letts.</i> , Vol. 36:1-10, (1987)			
✓	A35	MALIK et al., "New Trends In Photobiology (Invited Review) Bactericidal Effects Of Photoactivated Porphyrins - An Alternative Approach To Antimicrobial Drugs", <i>Journal of Photochemistry and Photobiology</i> , Vol. 5:281-293, (1990)			

Examiner Signature		Date Considered	9/05
--------------------	---	-----------------	------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.


⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/605,824
				Filing Date	10/29/2003
				First Named Inventor	James C. Kennedy
				Group Art Unit	1617
				Examiner Name	Unassigned
Sheet	3	of	6	Attorney Docket Number	067286-0276

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
A	A36	KENNEDY et al., "Topical Photodynamic Therapy For Cancers Of The Skin", <i>Canadian Dermatology Association Journal</i> , Vol. 5, No. 3, pp. 45-47, (1991)	
	A37	BICKERS et al., "Biosynthesis of Porphyrins in Mammalian Skin And In The Skin Of Porphyric Patients", <i>The Journal Investigative Dermatology</i> , Vol. 68:5-9, (1977)	
	A38	MALIK et al., "5-Aminolevulinic Acid Stimulation Of Porphyrin And Hemoglobin Synthesis by Uninduced Friend Erythroleukemic Cells", <i>Cell Differentiation</i> , Vol. 8:223-233, (1979)	
	A39	MALIK et al., "Destruction of Erythroleukaemic Cells By Photoactivation Of Endogenous Porphyrins", <i>Br. J. Cancer</i> , Vol. 56:589-595, (1987)	
	A40	MALIK et al., "The Role Of Hemin In The Regulation Of Heme Synthesis By Fetal Mouse Liver Erythroblasts In Culture", <i>Exp. Hemat.</i> , Vol. 7, No. 4, pp. 183-188, (1979)	
	A41	MALIK et al., "Regulation Of Hemoglobin Synthesis, Iron Metabolism, And Maturation Of Friend Leukemic Cells By 5-Amino Levulinic Acid and Hemin", <i>Differentiation</i> , Vol. 13:71-79, (1979)	
	A42	MALIK et al., "Inactivation Of Erythrocytic, Lymphocytic And Myelocytic Leukemic Cells By Photoexcitation Of Endogenous Porphyrins", <i>Journal of Photochemistry And Photobiology: Biology</i> , Vol. 4:195-205, (1989)	
	A43	HANANIA et al., "The Effect of EDTA And Serum On Endogenous Porphyrin Accumulation And Photodynamic Sensitization Of Human K562 Leukemic Cells", <i>Cancer Letters</i> , Vol. 65:127-131, (1992)	
	A44	SIMA et al., "Experimental Porphyric Neuropathy: A Preliminary Report", <i>Canada J. Neurol. Sci.</i> , Vol. 8, No. 2, pp. 105-114, (1981)	
	A45	KENNEDY et al., "Endogenous Protoporphyrin IX, A Clinically Useful Photosensitizer For Photodynamic Therapy", <i>J. Photochem. Photobiol. B: Biol.</i> , Vol. 14:275-292, (1992)	
	A46	SHIZHENG et al., "Endogenous Porphyrins In Murine Skin And Transplanted PAM-212 Squamous Cell Carcinoma Tissues After Injection of δ -Aminolevulinic Acid", <i>Chinese Medical Journal</i> , Vol. 108(4):286-290, (1995)	
	A47	YANG et al., "Treatment With 5-Aminolevulinic Acid And Photoactivating Light Causes Destruction Of Preimplantation Mouse Embryos", <i>Fertility and Sterility</i> , Vol. 63(5):1088-1093, (1995)	
	A48	HUA et al., "Effectiveness of δ -Aminolevulinic Acid-Induced Protoporphyrin As A Photosensitizer - For Photodynamic Therapy In Vivo", <i>Cancer Research</i> , Vol. 55:1723-1731, (1995)	
	A49	ASH et al., "New Drugs And Future Developments In Photodynamic Therapy", <i>Eur. J. Cancer</i> , Vol. 29A(12):1781-1783, (1993)	

Examiner Signature		Date Considered	9/05
--------------------	---	-----------------	------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/605,824
		Filing Date	10/29/2003
		First Named Inventor	James C. Kennedy
		Group Art Unit	1617
		Examiner Name	Unassigned
		Attorney Docket Number	067286-0276
Sheet	4	of	6

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
J	A50	KOENIG et al., "In Vivo Photoproduct Formation During PDT With ALA-Induced Endogenous Porphyrins", <i>J. Photochem. Photobiol. B: Biol.</i> , Vol. 18:287-290, (1993)	
	A51	VAN HILLEGERSBERG et al., "Current Status of Photodynamic Therapy In Oncology", <i>Drugs</i> , Vol. 48(4):510-527, (1994)	
	A52	YANG et al., "Photodynamic Ablation of Early Pregnancy in the Rat With 5-Aminolevulinic Acid: A Potential New Therapy For Tubal Ectopic Pregnancy in the Human", <i>Fertility And Sterility</i> , Vol. 62(5):1060-1065, (1994)	
	A53	WOLF et al., "Photodynamic Therapy for Mycosis Fungoides After Topical Photosensitization With 5-Aminolevulinic Acid", <i>Journal of the American Academy of Dermatology</i> , Vol. 31:678-680, (1994)	
	A54	FUKUDA et al., "Tumor-Localizing Properties of Porphyrins, in vitro Studies Using The Porphyrin Precursor, Aminolevulinic Acid, In Free And Liposome Encapsulated Forms", <i>Drug Des. Deliv.</i> , Vol.5:133-139, (1989)	
	A55	YANG et al., "Intrauterine 5-Aminolevulinic Acid Induces Selective Fluorescence And Photodynamic Ablation Of The Rat Endometrium", <i>Photochemistry And Photobiology</i> , Vol. 57(5):803-807, (1993)	
	A56	GRANT et al., "Photodynamic Therapy of Oral Cancer: Photosensitisation With Systemic Aminolaevulinic Acid", <i>The Lancet</i> , Vol. 342:147-148, (1993)	
	A57	LOH et al., "Oral Versus Intravenous Administration Of 5-Aminolaevulinic Acid For Photodynamic Therapy", <i>Br. J. Cancer</i> , Vol. 68:41-51, (1993)	
	A58	CHARLESWORTH et al., "The Use of 5-Aminolevulinic Acid (ALA) In Photodynamic Therapy (PDT)", <i>News And Views</i> , Vol. 18:99-100, (1993)	
	A59	KENNEDY, "Photochemotherapy - Clinical Aspects", Department of Oncology and Pathology, Photosensitisation. Edited by G. Moreno et al., pp. 453-463, (1988)	
	A60	KENNEDY, "Photodynamic Therapy With Endogenous Protoporphyrin IX: Basic Principles And Present Clinical Experience", <i>Journal of Photochemistry and Photobiology, B: Biology</i> , Vol. 6:143-148, (1990)	
	A61	DENNIS et al., "Protection of NIH 3T3 Cells From Infection By Trypomastigotes And Sphaeromastigotes Of J. Trypanosoma Cruzi, Telahuen Strain, By Porphyrins In The Presence And Absence of Light (630 and 690 NM)", <i>Parasitol.</i> , Vol. 75(6):970-976, (1989)	

Examiner Signature		Date Considered	9/05
--------------------	---	-----------------	------

*EXAMINER: Initial if reference considered. *If citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO
**INFORMATION DISCLOSURE
 STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 5 of 6

Complete If Known

Application Number	10/605,824
Filing Date	10/29/2003
First Named Inventor	James C. Kennedy
Group Art Unit	1617
Examiner Name	Unassigned
Attorney Docket Number	067286-0276

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	A62	BERLIN et al., "Normal Pathways, Studied With The Aid of N", <i>The Metabolism of δ-Aminolaevulic Acid</i> , Vol.64:80-99,(1956)	
	A63	BRAULT et al., "Fundamental Aspects In Tumor Photochemotherapy: Interactions Of Porphyrins With Membrane Model Systems And Cells", <i>Biochimie</i> , Vol. 68:913-921, (1986)	
	A64	DIVARIS et al., "Phototoxic Damage To Sebaceous Glands And Hair Follicles Of Mice After Systemic Journal Administration of 5-Aminolevulinic Acid Correlates With Localized Protoporphyrin IX Fluorescence", <i>American of Patbology</i> , Vol. 136(4):891-897, (1990)	
	A65	GROSSMAN, "PDT For Hirsutiem", <i>Lasers Surg. Med. Suppl.</i> , Vol. 7:A205, (1995)	
	A66	MALIK et al., "Topical Applction of 5-Aminolevulinic Acid, DMSO and EDTA: Protoporphyrin IX Accumulation In Skin And Tumours Of Mice", <i>Journal of Photochemistry And Photobiology B: Biology</i> , Vol. 28:213-218, (1995)	
	A67	KORELL et al., "Einsatz der Photodynamischen Lasertherapie in der Gynaekologie", <i>Gynaekol Geburtshilffliche Rundsch</i> , Vol. 35:90-97, (1995)	
	A68	UNTCH et al., "Synergistischer Effekt von Delta-Aminolaevulinsaeure und Photodynamischer Lasertherapie Anhand Eines In-Vitro-Modells Mit Dem ATP-Tumorchemosensitivitaetstest", <i>Gynaekol Geburtshilffliche Rundsch</i> , Vol. 35:85-89, (1995)	
	A69	SZEIMIES et al., "Topische Photodynamische Therapie In Der Behandlung Oberflaechlicher Hauttumoren", <i>Hautarzt</i> , Vol. 46:315-318, (1995)	
	A70	WOLF et al., "Photodynamic Therapy With 5-Aminolevulinic Acid:A Promising Concept For The Treatment of Cutaneous Tumors", <i>Dermatology</i> , Vol. 190:183-185, (1995)	
	A71	YANG, et al., "Evidence of Lasting Functional Destruction Of The Rat Endometrium After 5-Aminolevulinic Acid Induced Photodynamic Ablation: Prevention of Implantation", <i>Am. J. Obstet. Gynecol.</i> , Vol. 168(3):995-1001, (1993)	
	A72	WOLF, et al., "Topical Photodynamic Therapy With Endogenous Porphyrins After Application of 5-Aminolevulinic Acid", <i>J. Am. Acad. Dermatol.</i> , Vol. 28:17-21 (1993)	
	A73	GOFF et al., "Effects Of Photodynamic Therapy With Topical Application of 5-Aminolevulinic Acid On Normal Skin of Hairless Guinea Pigs", <i>J. Photochem. Photobiol. B: Biol.</i> , Vol. 15:239-251, (1992)	

Examiner
Signature

[Handwritten Signature]

Date
Considered

9/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete If Known	
		Application Number	10/605,824
		Filing Date	10/29/2003
		First Named Inventor	James C. Kennedy
		Group Art Unit	1617
		Examiner Name	Unassigned
		Attorney Docket Number	067286-0276
Sheet	6	of	6

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
A	A74	PENG et al., "Distribution And Photosensitizing Efficiency Of Porphyrins Induced by Application Of Exogenous 5-Aminolevulinic Acid In Mice Bearing Mammary Carcinoma", <i>Int. J. Cancer</i> , Vol. 52:433-443, (1992)	
	A75	SUROLIA et al., "De Novo Biosynthesis Of Heme Offers A New Chemotherapeutic Target In The Human Malarial Parasite", <i>Biochemical And Biophysical Research Communications</i> , Vol. 187(2):744-750, (1992)	
	A76	VAN HILLEGERSBERG et al., "Selective Accumulation Of Endogenously Produced Porphyrins In A Liver Metastasis Model in Rats", <i>Gastroenterology</i> , Vol. 103:647-651, (1992)	
	A77	FUKUDA et al., "Tumor-Localizing Properties Of Porphyrins in vivo Studies Using Free And Liposome Encapsulated Aminolevulinic Acid", <i>Comp. Biochem. Physiol.</i> , Vol. 102B(2):433-436, (1992)	
	A78	BEDWELL et al., "Fluorescence Distribution And Photodynamic Effect Of ALA-Induced PP IX In The DMH Rat Colonic Tumour Model", <i>Br. J. Cancer</i> , Vol. 65:818-824, (1992)	
	A79	REBEIZ et al., "Photodestruction Of Tumor Cells By Induction Of Endogenous Accumulation Of Protoporphyrin IX: Enhancement By 1, 10-Phenanthroline", <i>Photochemistry and Photobiology</i> , Vol. 55(3):431-435, (1992)	
	A80	ANDREONI et al., "Effects of HpD And Laser On Transformed and Corresponding Normal Cultured Cells: Differential Cytotoxicity As An In Vitro Model For Tumor Photochemotherapy", <i>Porphyrins in Tumor Phototherapy</i> , pp.143-155, (1993)	
	A81	ROBINO et al. "Porphyrin Metabolism In Human Neoplastic Tissues", <i>Panminerva Medica</i> , pp. 290-292	
	A82	SAMSOEN M., <i>Arsenal Medicamentoux Dermatologique</i> , Pg. 603-606, ISSN. 0752-5370 (1995) (Abstract)	
	A83	POTTIER et al., "Non-Invasive Technique for Obtaining Fluorescence Excitation and Emission Spectra In Vivo" <i>Photochemistry and Photobiology</i> , Vol. 44, No. 5, pp. 679-687, (1986)	
	A84	N. NAVONE et al., porphyrin biosynthesis in human breast cancer. Preliminary mimetic in vitro studies, <i>Med. Sci. Res.</i> , 1998; 16, 61-62, Buenos Aires, Argentina.	

Examiner Signature		Date Considered	5/05
--------------------	---	-----------------	------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/605,824
				Filing Date	10/29/2003
				First Named Inventor	James C. KENNEDY
				Group Art Unit	1617
				Examiner Name	Shahnam J. Sharareh
				Attorney Docket Number	067286-0276
Sheet	1	of	1		

[illegible]

Examiner Signature		Date Considered	9/8/05
-----------------------	---	--------------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.